• ImmunityBio reported that the QUILT-2.005 registrational trial in BCG-naïve NMIBC has reached database lock for Cohort A. This enables final efficacy analysis on 366 randomized patients treated with ANKTIVA plus BCG or BCG alone.
• The move to final analysis builds on an FDA-requested interim readout that showed statistically significant longer complete response duration with ANKTIVA plus BCG. This directly tests whether ImmunityBio can extend its bladder cancer franchise earlier in the treatment pathway.
• We will now look at how ImmunityBio’s broader investment narrative is influenced by this QUILT-2.005 database lock milestone and analysis.

Seize the momentum around ImmunityBio’s ANKTIVA readout and compare it with other targeted…